🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. The impact of extra-fine inhalation corticosteroid particles on small-airway disease in Chronic Obstructive Pulmonary Disease (COPD): a randomized, prospective cross-over trial.

    Pierre Fabre Australia Pty Ltd

    Chronic Obstructive Pulmonary Disease

    approved other active

    1 trial

  2. The placebo MDI is formulated as a suspension of spray-dried porous particles (consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC] and calcium chloride) in a hydrofluoroalkane propellant (HFA-134a). The placebo MDI uses the same excipients as active product but with absence of the active pharmaceutical ingredient (API)., Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease

    approved small molecule active

    1 trial

  3. The placebo has the same composition as the investigational medicinal product alkacitrat effervescent tablet 2 g/tab (with the exception of the active substance), is manufactured by the same manufacturer (uni-pharma kleon tsetis pharmaceutical laboratory s.a) and is not sterile., ALKACITRAT Αναβράζον δισκίο 2 g/tab

    Lacuna Pharma Pty Ltd

    Functional Dyspepsia

    approved small molecule active

    1 trial

  4. Ticagrelor followed with Methoxyflurane

    COLLEGIUM PHARMACEUTICAL, INC

    Unstable Angina

    approved small molecule completed

    1 trial

  5. Tirzepatide

    The First People's Hospital of Lianyungang

    Type 2 Diabetes Mellitus

    approved small molecule active

    1 trial

  6. Tislelizumab

    The First People's Hospital of Lianyungang

    Advanced NSCLC

    approved small molecule active

    1 trial

  7. Tislelizumab + cisplatin + paclitaxel

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    approved small molecule active

    1 trial

  8. Tocilizumab

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    approved small molecule active

    1 trial

  9. Tofacitinib and Acitretin Capsules.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary Cutaneous Amyloidosis

    approved small molecule active

    1 trial

  10. Topiramate

    Janssen Cilag International NV

    Epilepsy

    approved small molecule completed

    1 trial

  11. Tranexamic Acid

    The First People's Hospital of Lianyungang

    Postpartum Hemorrhage， Cesarean Section

    approved small molecule active

    1 trial

  12. Trastuzumab Rezetecan

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule active

    1 trial

  13. Trazodone

    United Therapeutics Europe Ltd

    Sleep Apnea

    approved small molecule active

    1 trial

  14. Triple antithrombotic therapy

    The First People's Hospital of Lianyungang

    Acute Coronary Syndrome (ACS)

    approved small molecule active

    1 trial

  15. Triple combination therapy group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  16. Trivalent live attenuated seasonal influenza vaccine

    The University of Hong Kong

    Influenza Virus Infection

    approved mab completed

    1 trial

  17. Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    1 trial

  18. Two doses of quadrivalent influenza vaccine

    Sinovac Research and Development Co.,

    Seasonal Influenza

    approved mab completed

    1 trial

  19. Ublituximab

    TG THERAPEUTICS, INC.

    Multiple Sclerosis

    approved mab active

    4 trials

  20. Urapidil Accord 5 mg/ml solución inyectable y para perfusión EFG, Trandate 5mg/ml Solution for Injection, Fenilefrina Altan 0,1 mg/ml solución inyectable y para perfusión.

    The George Institute

    Acute Ischemic Stroke

    approved small molecule active

    1 trial

  21. Use of Mitomycin-C (MMC) in trabeculectomy

    AEON Biopharma

    Glaucoma

    approved small molecule completed

    1 trial

  22. Use of an Implantable Loop Recorder

    Rhythm Pharmaceuticals Netherlands B.V.

    Syncope

    approved other completed

    1 trial

  23. VAB-7

    The First People's Hospital of Lianyungang

    Helicobacter Pylori

    approved small molecule active

    1 trial

  24. VERAPAMIL , NEBIVOLOL , PROPAFENONE , BISOPROLOL , AMIODARONE , FLECAINIDE , SOTALOL , DILTIAZEM

    Pari Pharma GmbH

    Asymptomatic Patients with frequent PVCs and normal LVEF

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources